5-LOXIN (Boswellia, 30% AKBA)

5-LOXIN is a standardized Boswellia serrata extract containing 30% AKBA (3-O-acetyl-11-keto-β-boswellic acid) that inhibits 5-lipoxygenase enzyme activity. This selective inhibition reduces inflammatory mediators like leukotrienes, providing targeted joint pain relief and cartilage protection.

Origin & History

5-LOXIN is a branded extract of Boswellia serrata, standardized to contain 30% acetyl-11-keto-beta-boswellic acid (AKBA). It is produced through a specialized extraction process that concentrates the active components.

Historical & Cultural Context

Boswellia, also known as frankincense, has been used in traditional Ayurvedic medicine for its anti-inflammatory properties. It holds cultural and religious significance in various ancient civilizations.

Health Benefits

- 5-LOXIN provides potent anti-inflammatory effects by inhibiting the 5-lipoxygenase enzyme, reducing joint pain and swelling. This can improve mobility and quality of life. - It supports joint health by maintaining cartilage integrity and reducing degradation. Healthy cartilage is crucial for pain-free movement. - 5-LOXIN enhances respiratory health by reducing inflammation in the airways. This can alleviate symptoms of asthma and improve breathing. - It supports digestive health by reducing inflammation in the gut lining. A healthy gut lining can prevent conditions like IBS. - 5-LOXIN promotes cardiovascular health by improving endothelial function. Enhanced endothelial function can lower blood pressure and reduce heart disease risk. - It aids in skin health by reducing inflammation and promoting collagen production. This can result in firmer, more youthful skin. - 5-LOXIN supports mental health by reducing neuroinflammation. Lower neuroinflammation can improve cognitive function and reduce the risk of neurodegenerative diseases.

How It Works

5-LOXIN's primary bioactive compound AKBA selectively inhibits 5-lipoxygenase (5-LOX) enzyme, blocking the conversion of arachidonic acid to inflammatory leukotrienes. This inhibition reduces pro-inflammatory mediators LTB4 and 5-HETE while preserving beneficial cyclooxygenase pathways. The extract also modulates NF-κB signaling and inhibits matrix metalloproteinases that degrade cartilage collagen.

Scientific Research

Clinical studies have demonstrated that 5-LOXIN effectively reduces inflammation and joint pain. RCTs and meta-analyses support its use in improving joint function and reducing symptoms of osteoarthritis.

Clinical Summary

Human trials with 5-LOXIN have shown significant improvements in joint function and pain reduction. A 90-day study with 60 osteoarthritis patients using 100mg daily demonstrated 65% improvement in pain scores and 61% improvement in joint function compared to placebo. Additional studies indicate onset of benefits within 7 days of supplementation. However, most clinical data comes from small-scale trials requiring larger confirmatory studies.

Nutritional Profile

5-LOXIN is a standardized Boswellia serrata extract concentrated to 30% acetyl-11-keto-β-boswellic acid (AKBA), its most pharmacologically active boswellic acid. Typical clinical doses range from 100–250 mg/day, delivering approximately 30–75 mg of AKBA per serving. Additional boswellic acids present include β-boswellic acid, 11-keto-β-boswellic acid (KBA), and α-boswellic acid at varying concentrations. AKBA demonstrates selective, non-redox inhibition of 5-lipoxygenase (5-LOX) with an IC50 of approximately 1.5 µM. Bioavailability of boswellic acids is notably enhanced when taken with a high-fat meal (up to 2-fold increase in Cmax), as these are lipophilic triterpenic acids. The extract contains negligible macronutrients (protein, carbohydrates, fat) in functional doses, and does not contribute meaningfully to vitamin or mineral intake. Phospholipid-complexed formulations (e.g., phytosome delivery) can further enhance AKBA absorption by improving gut wall permeability.

Preparation & Dosage

Typical dosages range from 100 mg to 250 mg per day. Consult a healthcare provider before use.

Synergy & Pairings

5-LOXIN pairs powerfully with Curcumin (standardized to 95% curcuminoids), as curcumin inhibits COX-2 and NF-κB pathways while AKBA targets 5-LOX, creating a dual-pathway anti-inflammatory blockade that reduces both prostaglandin and leukotriene synthesis simultaneously — this combination has shown additive reductions in joint pain markers in clinical studies. UC-II (undenatured type II collagen) complements 5-LOXIN's cartilage-protective effects by providing oral tolerance mechanisms to reduce autoimmune cartilage degradation, while AKBA specifically inhibits matrix metalloproteinase (MMP) activity to preserve the collagen matrix UC-II supports. Piperine (BioPerine, 5–10 mg) is a critical addition as a bioavailability enhancer — by inhibiting CYP3A4 and P-glycoprotein efflux, it increases AKBA and co-administered curcuminoid plasma concentrations by up to 20–30%; additionally, Omega-3 fatty acids (EPA/DHA) provide complementary 5-LOX substrate competition and downstream anti-inflammatory eicosanoid production (resolvins, protectins) that extend AKBA's leukotriene-suppressing effects.

Safety & Interactions

5-LOXIN is generally well-tolerated with mild gastrointestinal upset reported in some users. It may enhance the effects of anti-inflammatory medications and blood thinners due to its anti-platelet properties. Individuals with bleeding disorders or those taking anticoagulant medications should consult healthcare providers before use. Safety during pregnancy and lactation has not been established, so use should be avoided during these periods.